Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Li

Showing results (171-180 of 206) with videos related to

Pageof 21
Sort By:
European Urology|October 4, 2025
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the BladderAmanda A Myers, Ruchika Talwar, Zhigang Duan, et al.
Cancer Medicine|January 20, 2025
Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary TractMohammad Jad Moussa, Georges C Tabet, Arlene O Siefker-Radtke, et al.
Nature Medicine|June 18, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine|June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
European Urology|October 6, 2023
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial CarcinomaHeather L Huelster, Billie Gould, Elizabeth A Schiftan, et al.
Prostate Cancer and Prostatic Diseases|July 12, 2020
Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysisZhigang Yuan, Daniel Fernandez, Jasreman Dhillon, et al.
Nature Medicine|July 2, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
NPJ Precision Oncology|January 12, 2026
ShinyEvents: harmonizing longitudinal data for real-world survival estimationAlyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
European Urology|February 22, 2026
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer GroupShilpa Gupta, Roger Li, Patrick J Hensley, et al.
Research Square|August 13, 2025
ShinyEvents: harmonizing longitudinal data for real world survival estimationAlyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
Pageof 21

Showing results (171-180 of 206) with videos related to

Sort By:
Pageof 21
European Urology|October 4, 2025
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the BladderAmanda A Myers, Ruchika Talwar, Zhigang Duan, et al.
Cancer Medicine|January 20, 2025
Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary TractMohammad Jad Moussa, Georges C Tabet, Arlene O Siefker-Radtke, et al.
Nature Medicine|June 18, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine|June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
European Urology|October 6, 2023
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial CarcinomaHeather L Huelster, Billie Gould, Elizabeth A Schiftan, et al.
Prostate Cancer and Prostatic Diseases|July 12, 2020
Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysisZhigang Yuan, Daniel Fernandez, Jasreman Dhillon, et al.
Nature Medicine|July 2, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
NPJ Precision Oncology|January 12, 2026
ShinyEvents: harmonizing longitudinal data for real-world survival estimationAlyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
European Urology|February 22, 2026
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer GroupShilpa Gupta, Roger Li, Patrick J Hensley, et al.
Research Square|August 13, 2025
ShinyEvents: harmonizing longitudinal data for real world survival estimationAlyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
Pageof 21